This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
cannabis: Archive
2 Agriculture - Products Stocks to Watch Despite Industry Concerns
by Madhurima Das
The near-term outlook for the Zacks Agriculture - Products industry is uncertain. Stocks like ANDE and GRWG are braving the industry headwinds.
ANDEPositive Net Change GRWGNegative Net Change
agriculture basic-materials cannabis
Aurora Cannabis Pre-Q1 Earnings Analysis: Buy, Sell or Hold the Stock?
by Zacks Equity Research
ACB's global medical cannabis momentum stays strong, but near-term regulatory headwinds might have limited Q1 revenue upside.
CGCNegative Net Change TLRYNegative Net Change ACBNegative Net Change
cannabis medical
Do Options Traders Know Something About Aurora Cannabis Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to ACB stock based on the movements in the options market lately.
ACBNegative Net Change
cannabis medical medical-devices
GRWG Inks Distribution Agreement With V1 Solutions to Expand Globally
by Zacks Equity Research
GrowGeneration signs V1 Solutions to drive EU distribution and enters Costa Rica, entering deeper into global cannabis markets.
AGIPositive Net Change SSRMPositive Net Change HWKNPositive Net Change GRWGNegative Net Change
basic-materials cannabis
JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook
by Zacks Equity Research
Jazz reports dismal first-quarter results. The company revises its 2025 EPS guidance to account for the recently completed Chimerix acquisition.
JAZZNegative Net Change PBYIPositive Net Change NTLANegative Net Change
biotechs cannabis earnings marijuana medical pharmaceuticals
IIPR's Q1 Earnings Coming Up: Key Factors to Impact the Stock
by Zacks Equity Research
IIPR's Q1 2025 results may be impacted by property repossessions/sales, rent deferrals and partial tenant payments.
IIPRNegative Net Change LAMRPositive Net Change EPRPositive Net Change
cannabis finance marijuana reit
Buy, Sell or Hold JAZZ Stock? Key Tips Ahead of Q1 Earnings
by Sundeep Ganoria
Investors will likely focus on the sales performance of Jazz Pharmaceuticals' key neuroscience drugs, Xywav and Rylaze, when it reports Q1 results next week.
JAZZNegative Net Change AMRXNegative Net Change
biotechs cancer cannabis earnings-preview marijuana medical
JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play?
by Sundeep Ganoria
Both JAZZ and HRMY expect sales from neuroscience products to grow in 2025.
JAZZNegative Net Change HRMYNegative Net Change
biotechs cannabis marijuana marijuana-stocks medical pharmaceuticals
JAZZ Pharmaceuticals Stock Trades Near 52-Week Low: Time to Buy or Sell?
by Sundeep Ganoria
We advise investors to use the price dip in JAZZ stock as a buying opportunity despite the dynamic shifts in the regulatory landscape.
JAZZNegative Net Change EBSNegative Net Change
biotechs cannabis medical pharmaceuticals
Aurora Cannabis Rides the Global Legalization Wave: Should You Invest?
by Urmimala Biswas
ACB capitalizes on the rapidly evolving medical cannabis landscape, leveraging its EU GMP-certified manufacturing facilities, advanced genetics and deep regulatory knowledge.
CGCNegative Net Change ACBNegative Net Change OGINegative Net Change
cannabis healthcare marijuana marijuana-stocks medical